Generics rush after semaglutide patent expiry
The semaglutide patent expiry has opened the door for generic competition in India, with multiple domestic launches aiming to expand access for type 2 diabetes and weight management. Companies like Dr. Reddy’s have already introduced formulations, signaling intensifying price and access pressure globally. (theindianpractitioner.com) (thehansindia.com) (pharma.economictimes.indiatimes.com)
India’s primary semaglutide patent in India expired on March 20, 2026, triggering immediate generic entry opportunities. (msn.com)) Industry trackers counted more than 40 Indian drugmakers preparing day‑one launches, while aggregated lists forecast over 50 branded generic versions lining up for market entry. (fiercepharma.com)) Dr. Reddy’s announced DCGI approval and the commercial launch of Obeda as an injectable semaglutide available in 2 mg and 4 mg strengths, with company statements noting non‑inferiority vs. the reference product in domestic phase III studies. (economictimes.indiatimes.com)) Sun Pharma confirmed DCGI clearance for its semaglutide injectable, Noveltreat, based on a Phase III review, and regulators/press lists named Zydus, Mankind, Glenmark, Torrent, Alkem and USV among early entrants. (sunpharma.com)) Reported entry prices vary sharply across manufacturers: one industry report cited starter pricing near ₹1,290 per month, separate coverage noted doses being offered as low as ~₹220 each, and market reporting placed Dr. Reddy’s Obeda around ₹4,200 per month with company targets of up to ~60% discount versus branded analogues. (fiercepharma.com)) Regulatory and legal context shaped rollouts—Delhi High Court previously allowed Dr. Reddy’s to manufacture and export semaglutide but had barred domestic sales until March 2026—and the company has publicly flagged plans for oral semaglutide filings and “beyond‑the‑pill” services in FY2026–27. (economictimes.indiatimes.com))
